Characterised compound libraries to accelerate drug discovery

Amsbio provides researchers with access to an extensive portfolio of more than 325,000 fully characterised chemical compounds designed to streamline drug discovery and development. Covering everything from individual inhibitors, agonists, and natural products to ready-to-screen libraries, these high-quality and cost-effective reagents are suited to both academic and industrial applications.

With a focus on areas such as apoptosis, autophagy, cell cycle regulation, immunology, and signalling cascades, the collection includes over 20,000 small molecule inhibitors and agonists offering excellent membrane permeability, high chemical stability, and broad utility in both in vitro and in vivo studies.

Amsbio’s compound libraries, widely adopted by pharmaceutical and biotech high-throughput screening teams, encompass more than 800 curated sets. These include focused bioactive libraries, fragment libraries, natural product libraries, and diversity sets, each designed to probe specific targets or chemical space. All compounds are supplied with stringent quality assurance data - including HNMR, HPLC, and GC profiles - to confirm structural accuracy and purity.

The range also features over 16,000 natural products, such as flavonoids, alkaloids, terpenoids, coumarins, and saponins, supporting research across oncology, infectious disease, neurobiology, and metabolic disorders. In addition, Amsbio offers an expanding collection of PROTAC (Proteolysis Targeting Chimera) molecules. By leveraging the ubiquitin–proteasome system to selectively degrade proteins, PROTACs often demonstrate superior target engagement compared with traditional inhibitors.

Available in a variety of pack sizes to suit different research needs, Amsbio’s comprehensive offering of pre-characterised compounds are readily searchable by CAS number, name, and product code.

More information online